November/December 2011

TABLE OF CONTENTS

The Reshaping of the Pharmaceutical Industry Landscape: Partnerships & Alliances Are the Core of New Business Strategy

Frost & Sullivan Analyst Cecilia E. Van Cauwenberghe says the biopharmaceutical industry is facing the tough reality that drug development models that have served the industry well for many years, based on a vertically integrated structure with most of the R&D process performed in-house, have become unsustainable, thus the pharma industry is currently focusing on R&D activities toward a more personalized and cost-effective approach.

 

Pharma & Biotech Contract Services: Then & Now

Roundtable Discussion: Contributor Cindy H. Dubin asks several of the industry’s leading service providers about how the pharma climate has changed in the past 10 years, the struggles they face in today’s economy, and what they see for the future of pharma/provider partnerships.

 

Biopharmaceuticals: Opportunities & Industry Dynamics

Frost & Sullivan Analyst Ruplekha Choudhurie, MS, reports that with top pharmaceutical companies adding biologics to their pipeline, this is definitely an area of interest from a utility and commercial perspective. Companies like Pfizer, Merck, Novartis, GSK, Roche, and AstraZeneca have shown significant interest in biopharmaceuticals, and the R&D intensity has improved in the past 3 years. Speciality biopharmaceutical companies, such as Amgen, Shire, and Genzyme, are renowned for their robust pipeline of biologics and continue to innovate in this field.

 

Leading Technologies in Drug Delivery

Frost & Sullivan Analyst Ipshita Chakraborty, MS, suggests a positive outlook for drug delivery as the advent of novel drug formulations, such as peptide drugs, nucleic acid aptamers, and RNA interference, as well as new vaccine technologies, have augured the need for delivery technologies that can optimize the efficacy of these drugs and ensure that the cellular uptake is adequate.

 

Therapeutic Areas – Will This Area See Future Growth?

Frost & Sullivan Analyst Cecilia E. Van Cauwenberghe indicates the influx of generics is having a major impact on several therapeutic areas, prompting companies to move focus to other potentially lucrative therapeutic areas. With Big Pharma moving toward biotechnology, high-growth opportunities are moving toward oncology and other specialty areas for underserved markets.

 

Contract Services: A Stronghold in Drug Development & Clinical Trials for Pharma & Biotech

Frost & Sullivan Analyst Ipshita Chakraborty, MS, reports that a quick observation of the numbers reveals that more than half of the late-stage clinical compounds are currently externally sourced. This has given rise to the strong role of contract services in drug development, particularly during the clinical development stages.

 

Advanced Drug Delivery Technologies: Enabling Drug Reformulations & New Administration Routes

Hermann AM Mucke, PhD, believes no easy solution for the “pharmaceutical productivity crisis” can be reasonably expected and a new holistic business model is needed to drive the pharmaceutical industry’s revenue, as well as medical progress, in the 21st century; however, its design and implementation is a continuous and integrated process, not a single dramatic event.

 

Company Profiles

For each participating company, this section presents a special 2-page spread featuring their core technologies, capabilities, products, and services.

COVER

FEATURES